Peer-assisted telemedicine for hepatitis C and syphilis (PATHS)


Author: Spencer H, Cooper J, Jones K, Gailey T, Leichtling G, Leahy J, Cook R, Seaman A, Korthuis PT

Theme: Models of Care Year: 2024

Background: In the United States, rural people who use drugs (PWUD) face heightened barriers to hepatitis C virus (HCV) treatment. We recently completed a pragmatic randomized trial of peer-assisted telemedicine HCV treatment in rural Oregon which demonstrated improved rates of HCV cure compared to peer-facilitated usual care. Peer-Assisted Telemedicine for Hepatitis C and Syphilis (PATHS) has broadly implemented this intervention to widen the reach of services throughout the state of Oregon.

Description of model of care/intervention/program:
The core PATHS team, hosted at an academic medical center, consists of 0.5 full-time equivalency provider time and two staff members. Both staff members have lived experience of substance use. PATHS partners with community-based organizations in rural areas that employ peer recovery support specialists (“peers”), funded through a state Behavioral Health Division program (PRIME+). Peers perform rapid HCV screening and facilitate phlebotomy pre-treatment evaluation, telemedicine visits, medication adherence, and provide harm reduction services. Key collaborators include a nonprofit healthcare consulting firm, local health departments, and the state Behavioral Health Division.

Effectiveness:
From October 2022 to March 2024, PATHS diagnosed 117 cases of HCV in 16 of Oregon’s 36 counties. Of those diagnosed with HCV, 98 (84%) were linked to a telemedicine visit and 80 (68%) initiated HCV treatment. Of those who initiated treatment, 59 (74%) have completed treatment and 21 (26%) or are still on therapy. Of 27 patients completing treatment and ≥12 weeks follow-up, 100% demonstrated sustained virologic response at 12 weeks.

Conclusion and next steps:
PATHS implements peer-assisted telemedicine for hepatitis C with real-world effectiveness similar to that seen in a randomized trial. Next steps include low-barrier linkage to telemedicine-based medications for opioid use disorder, dried blood spot testing to replace phlebotomy in the pre-treatment evaluation, and scaling beyond Oregon. 

Download abstract Download poster